LAG3 and breast carcinoma: Comparison of the plasma concentrations of the soluble co-inhibitory immune checkpoints, PD-L1, LAG-3 and TIM-3 and the soluble dual-activity checkpoint, HVEM, measured in the group of healthy control subjects and the cohort of early breast cancer patients post-neoadjuvant chemotherapy (NAC).